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6Abstract
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common
cancer worldwide. Well-known risk factors include tobacco smoking and
alcohol consumption. Overall survival has improved, but is still low especially
in developing countries. One reason for this is the often advanced stage of the
disease at the time of diagnosis, but also lack of reliable prognostic tools to
enable individualized patient treatment to improve outcome. To date, the TNM
classification still serves as the best disease evaluation criterion, although it
does not take into account the molecular basis of the tumor. The need for
surrogate molecular markers for more accurate disease prediction has increased
research interests in this field.
We investigated the prevalence, physical status, and viral load of human
papillomavirus (HPV) in HNSCC to determine the impact of HPV on head and
neck carcinogenesis. The prevalence and genotyping of HPV were assessed
with an SPF10 PCR microtiter plate-based hybridization assay (DEIA), followed
by a line probe-based genotyping assay. More than half of the patients had
HPV DNA in their tumor specimens. Oncogenic HPV-16 was the most common
type, and coinfections with other oncogenic and benign associated types also
existed. HPV-16 viral load was unevenly distributed among different tumor
sites; the tonsils harbored significantly greater amounts of virus than other
sites. Episomal location of HPV-16 was associated with large tumors, and both
integrated and mixed forms of viral DNA were detected. In this series, we
could not show that the presence of HPV DNA correlated with survival.
In addition, we investigated the prevalence and genotype of HPV in
laryngeal carcinoma patients in a prospective Nordic multicenter study based
on fresh-frozen laryngeal tumor samples to determine whether the tumors were
HPV-associated. These patients were also examined and interviewed at
diagnosis for known risk factors, such as tobacco smoking and alcohol
consumption, and for several other habituations to elucidate their effects on
patient survival. HPV analysis was performed with the same protocols as in
the first study. Only 4% of the specimens harbored HPV DNA. Heavy drinking
was associated with poor survival. Heavy drinking patients were also younger
than nonheavy drinkers and had a more advanced stage of disease at diagnosis.
7Heavy drinkers had worse oral hygiene than nonheavy drinkers; however, poor
oral hygiene did not have prognostic significance. History of chronic laryngitis,
gastroesophageal reflux disease, and orogenital sex contacts were rare in this
series.
To clarify why vocal cord carcinomas seldom metastasize, we
determined tumor lymph vessel (LVD) and blood vessel (BVD) densities in
HNSCC patients. We used a novel lymphatic vessel endothelial marker (LYVE-
1 antibody) to locate the lymphatic vessels in HNSCC samples and CD31 to
detect the blood microvessels. We found carcinomas of the vocal cords to
harbor less lymphatic and blood microvessels than carcinomas arising from
sites other than vocal cords. The lymphatic and blood microvessel densities did
not correlate with tumor size. High BVD was strongly correlated with high
LVD. Neither BVD nor LVD showed any association with survival in our series.
The immune system plays an important role in tumorigenesis, as
neoplastic cells have to escape the cytotoxic lymphocytes in order to survive.
Several candidate HLA class II alleles have been reported to be prognostic in
cervical carcinomas, an epithelial malignancy resembling HNSCC. These alleles
may have an impact on head and neck carcinomas as well. We determined
HLA-DRB1* and -DQB1* alleles in HNSCC patients. Healthy organ donors
served as controls. The Inno-LiPA reverse dot-blot kit was used to identify
alleles in patient samples. No single haplotype was found to be predictive of
either the risk for head and neck cancer, or the clinical course of the disease.
However, alleles observed to be prognostic in cervical carcinomas showed a
similar tendency in our series. DRB1*03 was associated with node-negative
disease at diagnosis. DRB1*08 and DRB1*13 were associated with early-stage
disease; DRB1*04 had a lower risk for tumor relapse; and DQB1*03 and
DQB1*0502 were more frequent in controls than in patients. However, these
associations reached only borderline significance in  our HNSCC patients.
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9Abbreviations
BVD blood vessel density
CDK cyclin-dependent kinase
CR cumulative relative survival
CI confidence interval
DEIA DNA enzyme immunoassay
E early gene
EGF epidermal growth factor
FGF fibroblast growth factor
GERD gastro-esophageal reflux disease
HLA human leukocyte antigen
HNSCC head and neck squamous cell carcinoma
HPV human papillomavirus
HR hazard ratio
L late gene
LiPA line probe assay
LSCC laryngeal squamous cell carcinoma
LVD lymphatic vessel density
LYVE-1 lymphatic vessel endothelial marker 1
MHC major histocompatibility complex
OS overall survival
PCR polymerase chain reaction
PFS progression free survival
PlGF placental growth factor
pRb retinoblastoma protein
RRP recurrent respiratory papillomatosis
SPF short PCR fragment
TNM T - extent of primary tumor
N - absence or presence and extent of regional lymph node
metastasis
M - absence or presence of distant metastasis
UICC International Union Against Cancer
VEGF vascular endothelial growth factor
VEGFR vascular endothelial growth factor receptor
10
Introduction
Head and neck squamous cell carcinomas (HNSCCs) are known to have a
multifactorial etiology. Well-established risk factors include tobacco and alcohol
use and in some areas betel quid chewing as a risk for oral carcinoma. Other
risk factors proposed include poor nutritional status, genetic susceptibility, and,
in a subset of HNSCCs human papillomavirus (HPV). Overall survival of
patients who have contracted the disease has improved over the last two
decades, but diagnostic tools capable of predicting tumor growth are needed
for individualized treatment. To date, the best prognostic marker in use is the
TNM classification (UICC), which is based mainly on tumor size. This
classification is not able to distinguish neoplasias with infiltrative growth
potential from those with restricted local growth. The combined risk effect of
alcohol and tobacco is not only additive, but it seems to be multiplicative.1,2
Heavy alcohol users may also have worse survival than nonheavy users, but it
is difficult to separately analyze the molecular changes leading to this; alcohol
may act as a solvent for other carcinogens, and the metabolite acetaldehyde has
been shown to have carcinogenic properties.3,4
HPVs are small double-stranded DNA viruses featuring oncogenic
properties. They infect mucosal and skin epithelia. In cervical carcinomas, HPV
is needed for malignant transformation.5,6 Knowledge about HPV infections in
HNSCC has increased in the last twenty years. Studies suggest that the subset
of HNSCCs positive for HPV DNA has a better survival than that which is
HPV-negative.7,8 HPV-positive HNSCC is hypothesized to be different tumor
entity from HPV-negative HNSCC.9 While HPV may alter tumor behavior, its
prognostic value in HNSCC remains ambiguous.10,11
Neoplastic cells need angiogenesis to grow beyond one cubic
millimeter.12 Induced angiogenesis also requires lymphatic drainage. Solid
tumors tend to metastasize via lymphatics. Tumors originating from the upper
aerodigestive tract tend to metastasize to lymph nodes residing in the neck
area.13 This has a drastic effect on survival.14 Early-stage disease (T1-T2) at
diagnosis represents a curable disease managed with one treatment modality,
but when neck lymph nodes become involved (N1-N2) the treatment is
11
combined modality and the probability of a tumor-free outcome decreases.
Tumors originating from different subsites in the head and neck have different
metastatic potential; one explanation for this may be differences in blood and
lymphatic microvasculature.
Human leukocyte antigens (HLAs) play a role in cervical carcinoma, a
mucosal HPV-related cancer. Several HLA-class II haplotypes have been found
to be predictors of decreased15-18 or increased19,20 risk for cervical cancer. The
well-known risk haplotype is DQB1*0301-03,16,21,22 whereas DRB1*13 and
DQB1*060323-25 seem to be protective haplotypes. HNSCC share features with
cervical carcinomas, and the same HLA class II alleles may play a role in both
malignancies. Certain alleles have been found to be prognostic in recurrent
respiratory papillomatosis (RRP),26-28 disease associated with HPV 6 and
HPV11.
12
Review of the literature
1. Human papillomavirus (HPV)
HPVs are small, nonenveloped, double-stranded DNA viruses. They belong to
the Papillomaviridae family. Their genome is circular and about 7.9 kb in size,
comprising six early (E) genes and two late (L) genes. To date, over 100
papillomavirus types have been sequenced.29 Papillomaviruses are found in
many species, including birds and cattle, but humans are the most studied host.
Figure 1.
A schematic presentation of HPV-16 genome indicating the organization of
early (E) and late (L) genes.
1.1. Cutaneous and mucosal HPVs
Cutaneous HPV types (2, 4, 7) infect skin epithelia, causing warts in different
parts of skin depending on the HPV type.30 Epidermodysplasia verruciformis is
a rare hereditary disease in which infections with HPV-5 and -8 cause skin
carcinoma.31 The role of HPV in skin cancers of immunocompetent patients is
not fully understood.32,33
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Mucosal HPV types (6, 11, 16, 18) infect the anogenital area and the
upper respiratory tract, causing condylomas and anogenital warts,34,35
papillomas in the oral cavity, nose, and nasopharynx, inverted papillomas of
the nose and paranasal sinuses,36 and laryngeal papillomas.37,38 They are also
related to certain malignant tumors in these anatomical areas.
1.2. High- and low-risk HPVs
HPV classification into high- and low-risk types is based on molecular
epidemiological studies and functional evidence of the oncogenic potential of
certain HPV types.39 The high-risk HPV types (16, 18, 31, 33, 35, 52, 58, 59, 68,
73, and 82) are frequently associated with invasive squamous cell carcinoma;
the low-risk types (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81) are rarely found in
carcinomas and are often associated with premalignant or benign  disease.
1.3. HPV life cycle and cancer
HPV infects proliferative basal epithelial cells and has access to them usually
through microlesions. The E5, E6, and E7 have a proliferation-stimulating effect,
and they act in the early phase of infection. At suprabasal layers, the L1 and L2
genes start to act in viral assembly and release of virions with the shearing
epithelial cells. In productive infection, the viral genome stays episomal.
In carcinomas, part of the HPV genome integrates into the host cell
genome.40 During the integration part of the E2 sequence and the E4 and E5
coding sequences are deleted. The E5 gene is expressed only before integration,
and its functions are important in the early phase of infection. However, in
experimental models, it has been shown to promote transformation-associated
changes, making cells less dependent on epidermal growth factor (EGF).41-43 The
oncogenic E6 gene affects functions of several cellular proteins by binding
them,44,45 and it is also capable of immortalization of distinct cell lines on its
own.46 The first oncogenic effect reported for E6 was p53 binding and
subsequent inhibition of apoptotic signals,47,48 and another important function is
telomerase activation.49 E7 is the main transforming gene capable of inactivating
the retinoblastoma gene product,50,51 which releases the cell from growth arrest
to the S phase.52 It also suppresses CDK inhibitors53 and activates cyclins E and
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A.54 After viral integration into the host genome, E2 gene repression55,56 of the
E6 and E7 promoters ceases and synergistic function in transformation begins.
These oncogenic changes are properties of high-risk HPV E6 and E7 genes; the
counterparts in low-risk HPV are unable to immortalize cells.57,58 However, E6
and E7 of high-risk HPVs are not capable of converting normal cells to a
malignant phenotype without chemical and physical changes.59
The first associations between HPV and malignant tumors were reported
in 1974, when zur Hausen discovered HPV in cervical carcinoma.34 Later
convincing epidemiological evidence has linked HPV to cervical
carcinogenesis.5,60-63 The first cases of HPV in upper aerodigestive tract cancers
were reported at the beginning of the 1980s by Syrjänen et al.,64,65 who proposed
that HPV was involved in oral squamous cell cancers.
2. Angiogenesis in cancer
2.1. Angiogenic properties of tumorigenesis
Growth of normal and neoplastic cells is dependent on angiogenesis.12,66,67
Ability to induce blood vessel growth is not intrinsic to proliferating cells. To
progress to a size over one cubic millimeter, neoplasias must gain angiogenic
properties.68-71 In normal adult life, angiogenesis takes place only in pathological
events, with one exception, the highly controlled female reproductive cycle.72
At the in situ level, the neoplastic cells are influenced by angiogenic
molecules; vascular endothelial growth factor and acidic and basic fibroblastic
growth factors (VEGF, aFGF, bFGF), and anti-angiogenic factors (endostatin,
thrombospondin-1, angiostatin), and when the balance between these factors is
maintained, angiogenesis does not exist. As the neoplastic cells change to a
more invasive phenotype and angiogenic signals prevail over anti-angiogenic
signals (“angiogenic switch”), the tumor becomes vascularized and is able to
maintain sustained angiogenesis, one of the hallmarks of cancer.71,73 This
presumable “halfway” event in carcinogenesis has led researchers to study
tumor microvessel densities with endothelium-specific antibodies (CD31, von
Willebrand factor). Blood vessel density (BVD) is a prognostic factor in breast,
prostate, and head and neck carcinomas.74-76 These findings have launched
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studies of angiogenesis inhibitors; if vascular growth could be prevented, the
neoplastic mass would merely be a manageable chronic disease.77
Anti-angiogenic treatments include antibodies, soluble receptors, small-
molecule tyrosine kinase inhibitors, antisense oligonucleotides, aptamers, and
RNA interference. The most studied molecule in anti-angiogenic treatment is
monoclonal antibody against VEGF, bevacizumab (Avastin; Genentech Inc.).
In phase III trials, bevacizumab has been shown to increase overall survival
(OS) and/or progression-free survival (PFS) in colorectal, breast, and lung
cancer when combined with cytotoxic agents.78 However, the function of direct
and indirect anti-angiogenic therapy is still poorly understood, and in clinical
trials, these drugs behave unpredictably from phase I results. Jain et al.79 have
summarized the recent results of phase III trials of anti-angiogenic drugs. They
conclude that anti-angiogenic therapy may be effective in treating solid tumors,
but the treatment must be well planned for a specific patient group, which is a
challenge for clinicians. In addition, no useful marker exists to evaluate the
efficacy of anti-angiogenic therapy during the treatment period.
Table 1. Vascular endothelial growth factors and their receptors.
2.2. Lymphangiogenic properties of tumorigenesis
Tumor angiogenesis is crucial for tumor growth, and it potentially promotes
hematogenous metastasis;80 however, lymph node metastasis is clinically the
most important prognostic sign.81 Solid tumors tend to disseminate to sentinel
lymph nodes via lymphatic drainage. Tumor lymphangiogenesis and its
relation to lymphatic metastasis are not fully understood.82,83 Studies show that
VEGF
receptors VEGFR-1 VEGFR-2 VEGFR-3 Neuropilin-1
(Flt1) (Flk1/KDR) (Flt4)
VEGF VEGF VEGF VEGF-C VEGF
family VEGF-B VEGF-C VEGF-D
members PlGF VEGF-D
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a family of vascular endothelial growth factors (VEGF-(A), B, C, D and
placental growth factor) and their receptors (VEGFR-1, 2, 3, and neuropilin-1)
play a major role in angio- and lymphangiogenesis.84 Of these, VEGF-C and -D
promote lymphangiogenesis through activation of VEGFR-3. 85-87
In experimental studies, VEGF-C and -D are reported to speed up tumor
growth and promote spreading of tumor cells via the lymphatics.88,89 In clinical
studies, VEGF-C and -D are described as prognostic at different stages of
cervical carcinoma,90 and VEGF-D is an independent prognostic marker for
colorectal carcinoma91 and epithelial ovarian carcinoma.92 In these studies, high
VEGF-D expression in tumor tissues predicted a poor prognosis; epithelial
ovarian carcinoma patients with a high VEGF-D-expressing tumor a had poor
carcinoma-specific survival (RR 8.2  95% Cl 2.33-83.33).
These results reveal that the lymphatic drainage system is an accessible
route of local metastasis. Based on recent data, peritumoral lymphatics appear
to be more important in tumor dissemination than intratumoral lymph
vessels.93,94
3. The HLA system
3.1. HLA classification
The human leukocyte antigen (HLA) complex, located in chromosome 6,
comprises 200 genes, over 40 of which encode leukocyte antigens.95 Other genes
in the loci are not related to HLA; however, some are involved functionally
with the immune system.
The HLA genes functioning in immune response are categorized as
either class I or class II; these classes differ in structure and function.
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Figure 2.
A simplified illustration of the structure of HLA class I (A) and class II (B)
molecules. 2-microglobulin (2m) is the light chain of the class I molecule. The
-chain of the class I molecule has two peptide binding domains (1 and 2),
an immunoglobulin-like domain (3), a transmembrane region (TM), and a
cytoplasmic tail. Each of the class II - and -chains has four domains: the
peptide-binding domain (1 or 1), the immunoglobulin-like domain (2 or
2), the transmembrane region, and the cytoplasmic tail. PM=plasma
membrane (modified from Klein J & Sato A, NEJM 2000;343:702-9).
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Figure 3.
An overview of the HLA locus on chromosome 6 (modified from Klein J & Sato
A, NEJM 2000;343:702-9).
There are approximately 20 class I genes in the HLA loci, and three of these,
HLA-A, -B, and -C, termed classic genes, are the key players in immunology.
The loci of class II genes on chromosome 6 are determined with three letters:
the first (D) indicates the class, the second (M, O, P, Q, or R) is the family, and
the third (A or B) is the chain ( or ). For example, HLA-DQB are class II genes
of the Q family coding for -chains. The individual genes are differentiated by
Arabic numbers, and for separate numerous allelic variants of these genes is a
number preceded by an asterisk. HLA-DQB1*0303 stands for allelic variant
0303 of gene 1, which encodes the -chain of a class II molecule belonging to the
Q family. The function of both class I and class II molecules is the presentation
of pathogen-derived peptides to T-cells, thereby initiating the adaptive immune
response.
3.2. HLA and disease implications
Several human diseases are known to be associated with HLA. Distinct patterns
of HLA alleles display predispositions to certain diseases or protection against
them. Although associations observed in one population may not be found in
other geographic regions or ethnic groups, worldwide screening reports are
important in prediction of disease susceptibility and resistance.
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In autoimmune disease, failure to discriminate between self- and nonself
antigens leads to an immune response raised against autologous antigens of
normal body tissues. An HLA association has been recognized in type 1
diabetes,96 ankylosing spondylolitis,97 and celiac disease.98 Selected associations
between HLA markers and autoimmune diseases are listed in Table 2.
Table 2. HLA associations in selected autoimmune diseases (modified from
Klein J & Sato A, NEJM 2000;343:702-9).
HLA marker Associated disease Relative risk

B27 Ankylosing spondylolitis 87.4

B27 Reactive arthropathy, including Reiter's 37
 syndrome

DR3 Insulin-dependent diabetes mellitus 3.3
DQB1*0201 2.4
DR4 6.4
DQB1*0302 9.5
DR2 0.19
DQB*0602 0.15

DR3 Celiac disease 10.8
DR7,11 6-10

DR3 Dermatitis herpetiformis 15.9

DR3 Systemic lupus erythematosus 5.8
Studies show associations between infectious diseases and HLA genes as
well. Specific class I and II alleles are able to protect against a severe form of
malaria,99 clearance from hepatitis B100,101 and C102,103 is associated with distinct
HLA alleles. Certain HLA alleles are also associated with susceptibility to
persistence of these infections.102,104 An association with severe hantavirus
infections in subjects carrying a certain HLA haplotype has been reported.105
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HLA alleles predisposing to23 and protecting from106 cervical HPV infections
exist.
Generally, HLA class I disease associations involve cytotoxic T-
lymphocytes, whereas class II disease associations involve T-helper or -
suppressor lymphocytes. The reported disease associations seem to share an
interesting feature: associations that have been reproduced in different studies
are mainly linked to autoimmune diseases, while those connected to infectious
diseases apparently cannot be easily reproduced.107 This may be due to
differences in determining diseases and different patient selection criteria.
3.3. HLA and cancer
The involvement of the HLA system in cancer is not completely understood.
HLA and cancer prognosis used as search terms produces thousands of articles
about blood borne malignancies and hematopoietic diseases, but the immune
system plays an important role in development of solid tumors as well.
Carcinoma cells tend to express several surface proteins different from
those of their normal counterparts. Despite their abnormal behavior, they are
inefficiently recognized by cytotoxic T-cells, a possible result of cancer cells
downregulating MHC translation, but one may wonder why these abnormal
cells are not terminated by natural killer cells.108 Escape from the immune
system requires a complex modulatory capability, and several carcinomas have
been shown to possess these features. Downregulation or alterations in HLA
class I expression are reported in breast cancer,109 lung cancer,110 cancer of the
uterine cervix,111 and HNSCC.112 This is thought to be one of the escape
mechanisms from immune attack.113 Studies show impaired antigen processing
in HNSCC,114,115 and in addition dendritic cell maturation and a T-cell subset
imbalance116 lower the ability of the immune system to eliminate neoplastic
cells.
HLA class II associations have been investigated widely in cervical
carcinomas, an epithelial malignancy resembling HNSCC. Studies have
reported candidate alleles and haplotypes associated with risk for or protection
from cervical carcinoma and with disease outcome. To date, the strongest
protective association in these malignancies has been DRB1*13 and/or
DQB1*0603 alleles. The haplotype possessing the highest risk for cervical cancer
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is DRB1*1501-DQB1*0602. These findings were recently reviewed by
Hildesheim.17 Comprehensive population-based studies have revealed
discrepant results considering risk alleles in cervical cancers,15,16,23 with
candidate alleles varying between geographical areas, disturbing worldwide
risk mapping.
However, cervical carcinogenesis is also largely influenced by persistent
HPV infection, thus when estimating the impact of distinct HLA alleles on
cervical cancer risk, HPV status should be considered. HPV has been reported
to decrease the number of dendritic Langerhans cells in the female genital
tract.117 Moreover, HPV-positive cervical carcinomas are influenced by different
HLA alleles than their HPV-negative counterparts. Studies show over-
representation of certain class II alleles in patients with HPV-positive cervical
carcinomas25 and cervical intraepithelial lesions,22,25,118 which implicates poor
viral clearance in patients carrying these alleles. Few studies exist on the class II
associations in HNSCC.
4. Head and neck cancer
Head and neck squamous cell carcinoma (HNSCC) comprises epithelial
malignancies arising from the mucosa of the lips, oral cavity, oropharynx,
nasopharynx, hypopharynx, larynx, maxillary sinus, nasal cavity, ethmoid
sinus, and salivary glands. It is the fifth most common cancer in males and the
eight most common in females.119 The treatment of HNSCC is related to tumor
extent and function preservation; surgery or radiotherapy alone or in
combination with is the traditional treatment option, but use of concomitant
chemoirradiation is increasing due to significantly improved locoregional
control and overall survival.120-125
4.1. Etiology and risk factors
The annual total number of new HNSCC cases globally is over 600 000, with
350 000 deaths occurring.119 The total number of new cases in Finland in 2003
was over 600, and the annual death rate about 200.126 For most head and neck
cancer sites, the age-adjusted incidence rate is higher in men than in women;
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the estimated worldwide number of new cases of head and neck cancers in 2002
was 477 000 in males and 166 000 in females according to global cancer
statistics.119 The worldwide number of new laryngeal cancer in 2002 was 160
000; in Finland the corresponding figure in 2002 was 110 and this cancer was
much more common in males. The age-adjusted incidence rate in males has
decreased from 6.2 to 2.2/100 000 individuals between the 1960s and present;
the age- adjusted incidence rate in females for the same period has changed
little, from 0.4 to 0.2/100 000 individuals.126
Figure 4.
A sagittal view of the head and neck region (modified from Syöpätaudit 3rd.
Ed., Duodecim).
The etiology of HNSCC is considered multifactorial. Tobacco and alcohol abuse
are the best-known risk factors.127-129 Results of selected case-control
studies1,127,130 on the risk of tobacco smoking and alcohol are presented in Table
3. Ethanol itself is not carcinogenic,131 but acetaldehyde, a major metabolite of
ethanol, is carcinogenic in animals.4,132 Studies show that acetaldehyde may be a
paranasal sinuses
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significant carcinogen also in humans.133,134 Current data reveal that
acetaldehyde levels in saliva are higher in tobacco smokers than in nonsmokers
and that smoking combined with alcohol consumption may increase salivary
acetaldehyde levels up to 7-fold.135 This increases the the carcinogenic exposure
of the epithelium.
Table 3. Results from selected case-control studies evaluating the risk OR (95%
CI) of tobacco smoking and alcohol consumption in head and neck cancer.
a Results for male only; b Entire study population was male; c Oral cavity and
pharynx combined; NA - data not available
Evaluating the independent risk of alcohol is difficult because many
heavy alcohol users are also smokers. Studies have shown tobacco smoke to
pose a greater risk than alcohol for laryngeal squamous cell carcinoma (LSCC);
while alcohol intake without tobacco smoke possesses a risk for LSCC, it is far
lower than that of tobacco alone.136
Environmental tobacco smoke has also been reported to increase the risk
for HNSCC.137,138 In addition betel quid (Areca nut) chewing is a major risk
Tumor site
Oropharynx Oral cavity Pharynx Larynx Dose Ref.
14.3a 17.6 7.1  25 cigarettes/day 127
(4.2-48.0) (4.1-74.7) (3.3-15.4)
Heavy 2.8b  40 cigarettes/day 130
smoking (1.8-4.4)
42.9  25 cigarettes/day 1
(22.8-80.9)
3.4 3.6 2.1  60 drinks/wk 127
(1.7-7.1) (1.8-7.2) (1.2-3.8)
Heavy 8.8b  30 drinks/wk 130
drinking (5.4-14.3)
5.9  56 drinks/wk 1
(3.1-11.3)
79.6c 11.7 127
(NA) (NA)
Combined 37.7b 130
(NA)
177.2 1
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factor in some areas of Asia,139-141 and studies show that, besides oral carcinoma,
it is also an independent risk factor for carcinomas of the upper aerodigestive
tract.142 A history of gastroesophageal reflux disease (GERD) has been reported
to increase the susceptibility to a subset of HNSCC.143 Dietary risk for HNSCC is
high in people consuming low levels of fruits and vegetables.144-146 High intake
of fiber and vitamin C has a positive effect on survival from laryngeal and
hypopharyngeal cancers.147 However, assessing the influence of nutrition is
difficult because a large proportion of HNSCC patients are malnourished,148,149
and it is not known which micronutrients actually prevent the carcinogenesis.
Genetic susceptibility has also been proposed as an etiological factor.150,151
Studies have shown increased cancer risk in HNSCC patients’ relatives.
Inherited malfunction of the immune system, DNA repair systems, and cell
cycle control mechanisms may increase the susceptibility to malignant growth.
Occupational risk factors include hardwood dust, furniture making, and leather
tanning, which mainly cause adenocarcinomas of the sinonasal area, but to
some extent also pose a risk for squamous cell carcinomas.152-154
4.2. Tumor classification
Head and neck tumors are categorized according to the TNM classification
(Tables 1 and 2), which is based on guidelines set by the International Union
Against Cancer (UICC). The classification varies slightly depending on the
subsite of tumor origin. Generally, T is a measure of primary tumor mass, N
indicates whether lymph nodes are involved, and M indicates for distant
metastasis.
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Table 4. Tumor classification for glottic laryngeal cancer (UICC 2002).
Table 5. Stage classification for glottic laryngeal carcinoma (UICC 2002).
Stage 0 Tis N0 M0
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T1-2 N1 M0
T3 N0-1 M0
Stage IVA T1-3 N2 M0
T4a N0-2 M0
Stage IVB T4b Any N M0
Any T N3 M0
Stage IVC Any T Any N M1
TNM Tumor characteristics
Tx Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ
T1 Tumour limited to vocal cord(s)(may involve anterior or posterior
commissure) with normal mobility
a Tumour limited to one vocal cord
b Tumour involves both vocal cords
T2 Tumour extends to supraglottis and/or subglottis, and/or with
impaired cord mobility
T3 Tumour limited to larynx with vocal cord fixation and/or invades
paraglottic space, and/or with minor thyroid cartilage erosion (e.g. inner cortex)
T4
a Tumour invades through the thyroid cartilage, or invades tissues beyond
the larynx, e.g., trachea, soft tissues of the neck including deep/
extrinsic muscle of tongue (genioglossus, hyoglossus, palatoglossus,
and styloglossus), strap muscles, thyroid, oesophagus
b Tumour invades prevertebral space, mediastinal structures, or encases
carotid artery
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in single ipsilateral lymph node, 3cm or less in
greatest dimension
N2
a Metastasis in a single ipsilateral lymph node, more than 3cm but 
not more than 6cm in greatest dimension
b Metastasis in multiple ipsilateral lymph nodes, none more than
6cm in greatest dimension
c Metastasis in bilateral or contralateral lymph nodes, none more than
6cm in greatest dimension
N3 Metastasis in a lymph node more than 6cm in greatest dimension
Mx Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
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4.3. HPV in head and neck squamous cell carcinoma (HNSCC)
Morphological findings suggested involvement of HPV in oral squamous cell
carcinomas at the beginning of the 1980s.65 Some years later, HPV16 DNA was
identified with a hybridization technique in oral carcinoma.155 After these initial
findings, knowledge about viral etiology in HNSCCs has increased
dramatically.156-158 The most frequently detected high-risk HPV is type 16.159
HPV-18 and 33 are also found in head and neck malignancies, but their
incidence is lower than that of HPV-16. HPV infection is an important and
obligatory step in cervical carcinogenesis. When information about HPVs
ability to promote malignant transformation at the cellular level emerged, it
was considered to play a key role in a subset of head and neck cancers as
well.157 The prevalence of HPV in HNSCC varies depending on the detection
method used and on the tumor subsite. However, several studies have
discovered high prevalences in oropharyngeal tumors, especially tonsillar
carcinomas,160-163 whereas in laryngeal carcinomas great variation exists.157,164-167
Nevertheless, HPV DNA is less frequently present in laryngeal than in
oropharyngeal malignancies. Studies show relatively low prevalence of HPV
infection (16%) also in hypopharyngeal carcinomas.11,157,168 In contrast to cervical
carcinomas, the viral copy numbers in HNSCC, except in tonsillar carcinomas,
are low.169-171 Some studies have found HPV to have a positive influence on
prognosis,157,172 but contradictory reports also exist.173,174
HPV seroprevalence has been shown to be prognostic in head and neck
cancer.175 The HPV-16 seropositivity in this study was twice as high in patients
than in controls. The odds ratios for head and neck cancer in HPV-16
seropositive patients varied depending on the subsite, the highest being
oropharyngeal cancer and cancer of the base of the tongue.
At the molecular level, HPV-positive HNSCC displays different
characteristics than HPV-negative HNSCC. HPV-positive tumors have wild-
type p53,176 decreased expression of cyclin D and pRb, and upregulation of
p16,177-179 whereas HPV-negative tumors have not. These and other possible
molecular differences alter the behavior of the tumor and affect the prognosis.
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4.4. Lymphatic vessels and tumor metastasis in HNSCC
HNSCC are known to metastasize via the lymphatics.13 Nodal involvement of a
tumor is often associated with a more complex treatment. It would be useful if
tumors with a disseminating potential could be characterized already at
diagnosis.
Increased understanding of the importance of lymphatic spread to tumor
growth has launched studies of this topic in HNSCC also. However, the results
are somewhat ambiguous. Some studies show peritumoral lymphatic vessels as
prognostic of lymph node involvement,180,181 while others have found an
association with better survival.182 Most recently intratumoral lymphatics have
been presented as predictors of poor outcome.181-185 Interestingly, a recent
review by Alitalo et al.186 states that lymphatics lying in the tumor periphery are
the most important in tumor dissemination. HNSCC is a heterogeneous group
of tumors arising from the upper aerodigestive tract, and the density of the
lymphatic vessel network may differ according to the tumor subsite.
4.5. HLA class II associations in head and neck tumors
Recent studies reveal associations of class II alleles in recurrent respiratory
papillomatosis (RRP), a laryngeal premalignant condition caused by HPV-6 and
-11. Individuals carrying DRB1*0102 have an increased risk for RRP,27 and
DQA*0102 and DQA*0501/DQB1*0201 are risk alleles in the white American
population.28 Aaltonen et al.26 identified DQB1*0501 to be protective against
adult-onset laryngeal papillomatosis in a distinct subgroup of patients.
Recurrent respiratory papillomas seldom progress to invasive carcinomas187,188
and are genetically separate from invasive carcinomas.189 Potential risk alleles in
carcinogenesis or alleles associated with disease outcome may differ from those
described in RRP.
High-resolution HLA class II screenings in HNSCC are few. Tisch et al.190
determined HLA-DR6 antigens from 141 HNSCC patients and found HLA-DR6
to be associated with poor 5-year survival. The 5-year survival rate for HLA-
DR6-positive patients was 40%, whereas for HLA-DR6 negative patients it was
28
60%. Nevertheless, studies with adequate patient series and high-quality
methods are required to assess risk alleles and haplotypes in HNSCC.
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Aims of the study
Head and neck cancer is considered etiologically multifactorial. The most
commonly used prognostic tool for clinicians is the TNM classification, which
does not take into account the biological properties of the tumor. The surrogate
molecular markers in HNSCC could enable more individualized treatment
planning and effective therapy.
HPV is claimed to be involved in as many as 100 000 HNSCC cases
worldwide per year, the majority of which are oropharyngeal, especially
tonsillar cancers. When part of the HPV genome integrates into the host
genome, the viral gene products are able to disrupt the cell cycle, leading to
host cell changes towards a malignant phenotype. The major risk and
prognostic factors for HNSCC are tobacco and alcohol use and it is not fully
understood why HPV is less frequently present in other sites in the head and
neck than the oropharynx. HPV-associated HNSCC has been suggested to be a
different disease entity than that without  viral DNA.
A major issue influencing prognosis in HNSCC is tumor dissemination;
if a tumor with high-metastazing potential is detected early, treatment and
follow-up can be organized efficiently.
The immune system is able to detect and eliminate abnormal cells and
foreign objects. Neoplastic cells change their phenotype when developing the
ability to escape apoptosis and cell senescence. If the immune system is unable
to recognize these cells, tumor development is evident. HLA molecules play a
key role in the recognition of structures by the immune system. The individual
alleles or haplotypes have been demonstrated to have prognostic value in
several malignancies, but their impact on head and neck carcinogenesis is
unknown.
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The specific objectives of this thesis were as follows:
I. To determine the prevalence and physical status (episomal or
integrated viral DNA) of human papillomavirus in fresh-frozen
specimens of primary HNSCC.
II. To evaluate the impact of risk factors on the clinical outcome of
laryngeal carcinoma in a prospective Nordic multicenter study.
III. To analyze blood and lymphatic microvessel densities in primary
HNSCC tumor specimens, with a special focus on rarely metastasizing
vocal cord carcinomas.
IV. To investigate the effect of HLA class II allelic variance on head and
neck carcinogenesis.
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Patients and methods
1. Patients (I-IV)
Subjects in the studies were not consecutive. All patients fulfilling inclusion
criteria in each study were recruited to avoid a selection bias. In Study I,
HNSCC patients treated at Helsinki University Central Hospital during 1993-
2002 whose fresh-frozen samples were available and submitted at diagnosis to
ENT Clinic Tumor Bank participated. In Study II, LSCC patients who provided
tumor samples for HPV analysis at diagnosis during 2000-2003 were recruited.
They were from Helsinki University Central Hospital, Rikshospitalet University
Hospital, Oslo, and Karolinska University Hospital, Stockholm. In Study III,
samples were obtained from HNSCC patients who were diagnosed and treated
at Helsinki University Central Hospital during 1998-2001 and whose samples
were submitted to theENT Clinic Tumor Bank. In Study IV, the blood samples
collected for the ENT Clinic Tumor Bank from HNSCC patients diagnosed and
treated during 1997-2004 at Helsinki University Central Hospital were utilized.
All study protocols were approved by the Ethics Committee of each hospital.
Patient characteristics are presented in Table 6
2. Methods
2.1. DNA extraction (I, II, IV)
A fresh-frozen tissue sample was obtained during the tumor operation (Studies
I and II), and the tumor specimen was confirmed by a pathologist to contain a
minimum of 40% (Study I) or 20% (Study II) neoplastic cells.
DNA extraction was performed using a Qiagen DNA mini kit (Qiagen,
GmbH, Hilden, Germany) and tested for proper DNA quantity and quality
with routine -globin PCR.
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The buffy coat fraction was separated from each patient’s peripheral
blood sample and used for DNA extraction (Study IV) with a FlexiGene DNA
extraction kit (Qiagen, GmbH).
Table 6. Patient characteristics in Studies I-IV.
Characteristics Study I Study II Study III Study IV
n (%)
Origin
Finnish 61 (100) 11 (16) 60 (100) 162 (100)
Swedish 6 (9)
Norwegian 46 (67)
Other 6 (9)
Gender
Male 50 (82) 62 (90) 44 (73) 114 (70)
Female 11 (18) 7 (10) 16 (27) 48 (30)
Age
 65 yrs 42 (69) 36 (52) 39 (65) 109 (67)
> 65 yrs 19 (31) 33 (48) 21 (35) 53 (33)
Tumor site
Hypopharynx 10 (16) 8 (13) 8 (5)
Tonsil 5 (8) 4 (7) 22 (14)
9 (15) 3 (5) 5 (3)
Mobile tongue 6 (10) 5 (8) 26 (16)
Tongue (CNA) 3 (2)
Floor of the mouth 4 (7) 9 (6)
Larynx 18 (30) 69 (100) 33 (55) 61 (38)
Vocal cord 22 (37)
Glottis 45 (65) 2 (3)
Supraglottis 11 (16) 4 (7)
NA 13 (19) 5 (8)
Nasopharynx 10 (6)
Oral cavity, other 13 (21) 3 (5) 18 (11)
Stage
I 6 (10) 40 (58) 23 (38) 60 (37)
II 12 (20) 9 (13) 11 (18) 20 (12)
III 14 (23) 10 (15) 9 (15) 18 (11)
IV 29 (48) 10 (15) 15 (25) 55 (34)
NA 2 (3) 9 (6)
Alcohol
Heavy use 12 (17)
Nonheavy use 51 (74)
NA 6 (10)
Tobacco
Nonsmoker 2 (3)
Smoker 67 (97)
<10 cigarettes/day 9
10-20 49
>20 7
NA 2
CNA = classification not available
NA = data not available
Base of tongue
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2.2. HPV PCR  and genotyping (I, II)
The detection of HPV DNA using SPF10 PCR was done by a microtiter plate-
based probe hybridization assay (DEIA) and genotyping by a line probe-based
genotyping assay described in detail elsewhere (Studies I and II).191 In addition,
a single-phase PCR with primers FAP59/64192 and a nested PCR with primers
CP65/70 and CP66/69193 (Study I) were both performed to detect the majority
of cutaneous and mucosal HPV types. A nested PCR with consensus primers
(Study II) My09/11194 and GP5+/6+195 was also performed.196
Real-time PCR (Study I) was performed using an ABI Prism 7700
Sequence Detection System (PE Applied Biosystems, Perkin-Elmer, Wellesley,
MA). Amplification and quantification of E2 and E6 were carried out
simultaneously in a separate reaction tube.
2.3. Immunohistochemistry (I, III)
HPV L1 structure protein immunostaining (Study I) was conducted to examine
L1 structural protein expression in HNSCC. We used HPV-33 L1 monoclonal
antibody, which cross-reacts with HPV L1 proteins of most HPV types197 (a kind
gift from M. Sapp, University of Mainz, Germany), with Ventana DAB Kit
(Ventana Medical Systems, Inc., Tucson, AZ) in a Ventana Discovery automated
ISH-IHC Slide Stainer (Ventana Medical Systems).
For tumor lymphatic and blood vessel density determination (Study III),
the antibodies used were a polyclonal rabbit IgG antibody against human
LYVE-1198 (a kind gift from Dr. David Jackson, Weatherall Institute of Molecular
Medicine, John Radcliffe Hospital, Oxford, UK) to detect lymphatic vessels, and
a monoclonal mouse anti-CD31 antibody (Novocastra Laboratories Ltd.,
Newcastle, UK) to detect blood vessels. To determine the blood vessel density
(BVD) and the lymphatic vessel density (LVD), the section was first scanned
using low magnification, after which two areas (hot spots) showing the highest
density of vessels within the tumor or at the tumor margin (in case of lymphatic
vessels) were selected.199 The average vessel count was then determined by
counting all immunostained vessels at the two hot spots from one section using
a 200 x magnification field corresponding to an area of 0.95 mm2. Similar vessel
counts were obtained with and without using an ocular grid. All vessel counts
were assessed without knowledge of the clinical data.
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2.4. HLA-DRB1 and -DQB1 sequencing (IV)
HLA-DRB1* (01, 03, 04, 07, 08, 09, 11, 12, 13, 15) and HLA-DQB1* (0201, 0202,
0203, 0301, 0302, 0303, 0402, 0501, 0602, 0603, 0604, 0614) alleles were
determined with the Inno-LIPA reversed-dot blot kit (Innogenetics, Dartford,
UK). The sequencing was performed at The Finnish Red Cross, Blood
Transfusion Service, Helsinki, Finland.
2.5. Statistical analysis (I-IV)
Study I - To investigate dependence between explanatory variables, we
performed Fisher’s exact test (two-tailed). All p-values of less than 0.05 were
considered statistically significant. The relationships between survival times
and expalanatory variables were studied with the Cox proportional hazards
model.
Study II - Fisher’s exact test was applied to test the equality of response
probabilities in two patient groups. Shifts in age distribution between two age
groups were detected using the exact Wilcoxon-Mann-Whitney test with
StatXact version 7 (Cytel Inc., Cambridge, MA). Survival of the patients was
estimated by the actuarial method and corrected for competing causes of death
by estimating relative survival. The relative survival rate is defined as the ratio
of observed and expected survival rates of a comparable group of patients from
the general population matched by country, sex, age, and calendar time. The
patient survival was measured by the cumulative relative survival rate (CR)
corrected for heterogeneity in patient withdrawal.200 Likelihood ratio tests for
differences in relative or observed survival rates between patient groups during
the entire follow-up period were applied.201 Life table parameters were
estimated and tests conducted using survival package SURV3 version 3.01
(Finnish Cancer Registry, Helsinki, Finland). Proportional hazards models, the
hazard ratios (HRs) of death, were obtained202 with PROC PHREG using
statistical software SAS release 8.02 (SAS Institute Inc., Cary, NC). Ties in
survival were handled with the exact method. The patients were followed up to
the end of October 2005.
Study III - Correlations between CD31 and LYVE-1 vessel counts were
calculated with the Spearman rank correlation test and the vessel count was
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regarded as a continuous variable. CD31 and LYVE-1 scores between groups
were compared with the Mann-Whitney test. Frequency tables were analyzed
with chi-square test. Variables that predict the presence of regional metastases
were assessed using logistic regression. All p-values are two-tailed.
Study IV - Fisher’s exact test (2-tailed) was used for Cross-tabulations
between different haplotypes. A p-value of less than 0.05 was considered
significant.
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Results and discussion
1. HPV prevalence and viral load in HNSCC (I)
1.1. HPV prevalence and genotypes
Of the 61 HNSCC samples, 37 (61%) were positive for HPV. The most prevalent
HPV type was HPV-16 (31/37, 84%). HPV-33 was found in 10/37 positive
samples (27%). Multiple infection was observed in 8/37 samples (22%). The
frequency of HPV-positive samples varied according to anatomical site: 5/5
(100%) in tonsil, 11/15 (73%) in tongue, 7/13 (54%) in other oral cavity, 9/18
(50%) in larynx, and 5/10 (50%) in hypopharynx. The differences in HPV
prevalence between anatomical sites did not reach statistical significance in this
material. Only eight samples were HPV-positive (either HPV-16 or -33) with
FAP59/64, CP65/70, and CP66/69 primers. No cutaneous types were found.
In line with other studies,8,160,170 we observed a high prevalence of HPV in
tonsillar carcinomas (Fig. 1, Study I), suggesting a causal role of HPV in this
subset of HNSCC.203,204 HPV prevalence in the larynx and hypopharynx was
higher in our material than in other studies, where the prevalence in both
laryngeal165,167 and hypopharyngeal11,157,168 carcinomas was low. This is likely a
result of our small patient pool, and therefore, must be interpreted with
caution. In this series of Finnish patients, HPV prevalence in laryngeal
carcinomas was higher than in our larger prospective laryngeal carcinoma
series (Study II), in which heterogeneous material from different Nordic
countries was investigated.
1.2. HPV viral load and physical status (I)
HPV viral load and physical status were analyzed in 25 HPV-16-positive
samples with an adequate amount of DNA for analysis. A large variation
between viral loads in different HNSCC samples was noted. All five tonsillar
samples harbored a very high viral load, 46 620 to 4 901 400 copies of E6/10 000
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cells, whereas nontonsillar samples harbored only 1 to 677 copies of E6/10 000
cells (Table 2, Study I).
HPV DNA existed in all forms: episomal (n=8), integrated (n=11) and
mixed (n=4). Large tumors (T3 and T4) were overrepresented in the episomal
HPV DNA group as compared with the integrated (p=0.0181) and mixed
(p=0.019) groups. This finding suggests that in these T3-T4 tumors HPV has not
been the initiating factor in carcinogenesis; instead the virus may have infected
malignant cells already featuring immortality and infiltrative growth.
1.3. Expression of viral capsid protein in HNSCC (I)
HPV L1 protein was not detected in the tissue sections of HPV-positive tumor
samples. This was also true for the high viral load-containing tonsillar
carcinoma specimens, although our positive controls, cervical intraepithelial
neoplasia III and juvenile-onset laryngeal papilloma samples, showed strong
expression of L1.
The absence of late capsid protein expression in carcinomas is probably
due to synthesis of L1 taking place mainly in productive infections,205 where
epithelial differentiation is seen, and not in carcinomas. Epithelial productive
infection requires terminal differentiation of infected cells, which activates the
synthesis of capsid proteins. HPV capsid protein expression has previously
been detected in premalignant lesions and in keratosis.205 In carcinomas, the
prevalence of capsid protein expression is reported to be low.206
1.4. Prognostic significance of HPV status (I)
We found no significant difference in the survival of HPV-positive and HPV-
negative patients. HPV status had no effect on survival in the whole series or
when analyzed separately for different anatomical sites. This result is probably
due to the small number of patients and the relatively short follow-up (mean
24.5 months). Moreover, the study design was not the most suitable for reliable
survival analysis. Previous studies have shown better survival for HPV-
positive patients. 169,207,208 However, some reports fail to confirm this.209,210 While
HPV may be a marker for better prognosis in tonsillar carcinomas, as suggested
by Mellin et al.,8,169 or in distinct patient groups such as patients with an
advanced stage of the disease at diagnosis,211 HPV DNA may not be prognostic
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in all head and cancers. Moreover, lifestyle habits have a strong effect on the
survival in the malignancy; Ringström and colleagues208 noted that HPV-
positive patients consumed less alcohol than their HPV-negative peers.
For analysis of the impact of HPV infection on the clinical outcome of
head and neck cancer, studies with larger patient pool are needed. A long-term
follow-up and an adequate number of patients are required for a reliable
survival study.
2. Roles of HPV, tobacco and alcohol in laryngeal carcinomas (II)
2.1. HPV prevalence (II)
No HPV DNA was found with My09/11 and GP5+/6+ primers. The SPF10
PCR hybridization assay revealed three HPV-positive cases; two were positive
for the DEIA and not identified by the SPF10 Line probe assay, and one was
HPV-16.
HPV DNA was present in only three samples (4.4%), implying that HPV
does not play a key role in laryngeal carcinogenesis. Recently, several studies
have connected HPV to oropharyngeal and especially tonsillar malignancies,
and reports on laryngeal carcinomas show low prevalences of HPV DNA.9,167,212
Few studies have assessed HPV prevalence in laryngeal
premalignant/dysplastic lesions. Fouret et al.213 found HPV-16 DNA in 6/57
samples in a series of different stages of dysplasia; however, the samples
infected with HPV were mostly mild dysplasias. Low HPV prevalence rates in
dyplasias were also reported by Gorgoulis et al.214 However, Azzimonti et al.205
detected HPV DNA in 56% (28/50) of their series comprising different stages of
dysplasia. Nevertheless, their HPV-positive lesions were mostly mild
dysplasias.
Situated in the larynx is an epithelial junctional area similar to that in the
uterine cervix, which may serve as a potential infection site for HPV.
Interestingly, HPV does not seem to have a major role in laryngeal
carcinogenesis, despite being the best-known risk factor for cervical carcinoma.
The benign lesions laryngeal papillomatosis215 and genital warts (condyloma
accuminata)38,216 are, however, both caused by HPV types 6 and 11, but HPV
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does not have the same promoter role in malignant disease of the upper
aerodigestive tract as in cervical carcinoma.
2.2. Factors associated with survival (II)
Tobacco smoking and alcohol consumption are the best-known risk factors for
LSCC and are powerful markers of poor clinical outcome. We were unable to
distinguish the effect of smoking on individuals from that of drinking in
survival analysis because only three patients were nonsmokers. We therefore
categorized the patients as heavy ( 30 pack years, one pack year = smoking of
one pack of cigarettes/day for a period of one year) or nonheavy smokers and
compared survival between these two groups, also analyzing the impact of
other possible prognostic factors on survival.
The cumulative relative survival (CR) decreased by about 5% per year
up to four years of follow-up among all LSCC patients and by more than 10%
during the fifth year of follow-up (Figure 1, Study II). We found that heavy
drinkers had a worse 5-year CR, 0.38 (95% confidence interval (CI), 0.15–0.71),
than nonheavy drinkers, 0.89 (95% CI 0.69–1.01). The difference in relative
survival during the entire follow-up between the drinker groups was
significant (p=0.01) in favor of the proportional hazards hypothesis. Heavy
smokers had a lower 5-year CR, 0.60 (95% CI 0.33–0.86), than those not smoking
heavily, 0.92 (95% CI 0.70–1.05), but the difference in relative survival during
the entire follow-up was not significant. The relative as well as the observed
survival rates were not different during the entire follow-up between the
groups of localized and advanced LSCC, patients aged <65 and 65 years at
diagnosis, and patients with good oral hygiene and poor oral hygiene. The age
distributions did not differ between the drinker groups (p=0.23).
The proportion of advanced stage of LSCC was different between heavy
and nonheavy drinkers (p=0.01), being higher among heavy drinkers. The
proportion of patients with poor oral hygiene was different between heavy and
nonheavy drinkers (p=0.02), higher among heavy drinkers. The age- and stage-
adjusted hazard ratio (HR) for death associated with heavy alcohol drinking
was 3.0, although the confidence interval was wide (95% CI 1.1–8.2). In the
same model, the HR for death was also significantly increased, 3.3 (95% CI
1.1–9.6), among LSCC patients at least 65 years at diagnosis compared with
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younger patients. The HR associated with an advanced stage of LSCC was
nonsignificantly increased, 2.2 (95% CI 0.8–5.7). Neither interactions between
age, stage, and heavy alcohol drinking nor adding a variable for heavy tobacco
smoking or poor oral hygiene and their interactions with the previously
mentioned factors improved the model. The null hypothesis of a multiplicative
joint effect of heavy alcohol drinking and heavy tobacco smoking was not
rejected.
History of chronic laryngitis, gastroesophageal reflux disease (GERD) or
orogenital sex contacts was rare in our LSCC patients; no association was
present between these parameters and patient outcome.
Case-control studies have shown the risk for HNSCC to be multiplicative
when a patient has a history of both smoking and heavy drinking.1,2,217
However, few studies exist on nonsmoking alcohol drinkers and laryngeal
cancer. Bosetti et al.136 found individuals consuming over 8 drinks/day to have
an increased risk for LSCC (OR 2.46, 95% CI 0.98-6.2), and for nondrinking
smokers the risk was far greater (OR 9.38, 95% CI 3.35-26.26). Tuyns et al.218
observed only a slight increase in relative risk for heavy alcohol use ( 80 g
ethanol/day). Burch et al.219 measured lifetime alcohol consumption and found
lifetime consumption of over 737 kg alcohol to increase the risk for LSCC (RR
7.7), but this result was obtained from a very small group of patients. Survival
reports concerning the effect of smoking and drinking on LSCC are
controversial. Crosignani et al.220 reported alcohol intake not to have an effect
on survival, and Pradier et al.221 showed a similar result with tobacco smoking.
Nevertheless, it seems that in LSCC smoking has a stronger effect on survival
than alcohol.147,218,220,222
Estimate the actual borderline risk of alcohol intake in cancer is difficult.
Tobacco smoking is considered hazardous at any level, although reports show
differences in risk between heavy and nonheavy smoking and different tar-
yield levels. Studies classify alcohol intake as lifelong consumption or absolute
alcohol consumed during different time periods. As Polesel223 criticized, the
result of a study can easily be altered by changing the cut-off points for
consumption.
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3. Blood and lymphatic vessels densities in HNSCC (III)
3.1. Tumor lymphatic vessel density (LVD)
LYVE-1-positive staining was mainly present in thin-walled lymphatic
structures and in tissue macrophages. Most positive lymph vessels resided in
the peritumoral area or in the tumor front. Twenty-four of the samples (40%)
were LYVE-1-negative. The lymphatic vessel densities (LVDs) were
investigated by two observers and the agreement was good (Spearman rank
correlation coefficient 0.88). Intratumoral lymph vessels were identified in 12 of
the 36 cases that showed staining for LYVE-1.
The median tumor LVD was 5/mm2 (range 0 to 29/mm2), and high
lymph vessel counts were associated with high blood vessel counts (p=0.002,
Spearman rank correlation coefficient 0.41). The LVD was not significantly
associated with the tumor size (Table 2, Study III, p=0.52), histological grade
(p=0.33), or patient’s age at diagnosis (p=0.091). Vocal cord carcinomas had a
lower LVD than head and neck carcinomas at other sites (Table 2, Study III,
p=0.016). Intratumoral lymph vessels were detected at about an equal frequency
in vocal cord and other carcinomas (18% vs. 22%, respectively, p=0.75), but
peritumoral lymph vessels were less common in vocal cord carcinomas (6/22,
27% vs. 22/38, 58%, p=0.017). Peritumoral LVD was also smaller in vocal cord
carcinomas than in the rest of the cancers (median 0/mm2 vs. 6/mm2; p=0.026).
3.2. Tumor blood vessel density (MVD)
CD31-expressing microvessels were present intratumorally, at the
tumor edge, and along the peritumoral rim. Microvessel density
was not associated with tumor size (Table 2, Study III, p=0.79),
histological grade (p=0.76), or age at diagnosis (p=0.30). The median
BVD was smaller in vocal cord carcinomas than in other HNSCCs
(Table 2, Study III, p=0.006).
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Figure 5.
LYVE-1 immunostaining shows lymphatic vessels in the tumor margin. 200 x
magnification.
Figure 6.
Intra- and peritumoral blood vessels immunostained with CD31 antibody. 200 x
magnification.
3.3. Associations of BVD and LVD with regional metastasis
Primary tumor size and tumor location in the vocal cords were the most
important single predictive factors for the presence of regional metastases at
diagnosis in a logistic regression model (p=0.010 and p=0.020, respectively).
Since only one vocal cord carcinoma (5%) had given rise to regional metastasis,
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we evaluated the predictive value of BVD and LVD among the rest of the
carcinomas (n=38). In this subset, tumor size predicted best the presence of
regional metastases (OR 2.2, 95% CI 1.1 to 4.5, p=0.035). Addition of neither
BVD nor LVD to the model improved the accuracy.
Figure 7.
Blood vessel density was not associated with tumor size.
Figure 8.
Lymphatic vessel density was not associated with tumor size.
Intratumoral LVDs found in cancers are generally lower182,185,199,224-228 than
peritumoral LVDs182,199,225,228,229 or LVD of normal structures.225,230 Recent reports
have assessed LVD in HNSCC in general.182,231 Maula et al.182 found HNSCC
patients with intratumoral lymph vessels to have, a poor outcome but LVD was
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not an independent prognostic marker in multivariate analysis. To date, the
prognostic significance of LVD remains unclarified. Peritumoral lymphatics
have been hypothesized to be key elements in tumor dissemination,186 but LVD
might not be the best way to estimate peritumoral lymphatics since vessel
numbers may be smaller, they may be tortuous, and a single vessel may appear
several times in one cross-section.232
4. HLA-DRB1* and -DQB1*  associations in HNSCC (IV)
4.1. Candidate prognostic alleles
Our a priori alleles, DQB1*0501 and DR6 (DRB1*13,14), were selected because
they were previously reported to have a role in recurrent respiratory
papillomatosis (RRP)26 and HNSCC,190 and DQB1*0201 because it may be
prognostic in RRP and cervical carcinomas.20,27 In the series of 162 HNSCC
patients, our findings on candidate prognostic alleles remained only
implicative. HLA-DQB1*03 (DQB1* 0301,0302,0303) was more often found in
patients than controls (p=0.051, Fisher’s exact test, two-tailed). A protective
tendency was observed with allele DQB1*0502, as it was more common in the
control group.
Patients with DRB1*03 more often had a node-negative disease at
diagnosis (p=0.036). HLA-DRB1*04 was more frequent in patients with relapse-
free disease than in patients who developed a relapse (p=0.058). Patients
carrying DRB1*08 or DRB1*13 had smaller tumors at diagnosis than those
lacking both (chi-square test likelihood ratio, 0.036 and 0.04, respectively).
We found no disease associations with the DRB1*1501-DQB1*0602
haplotype, the best-known risk allele for cervical cancer,17 and HLA-DQB1*0501
was also evenly distributed between patient and control groups.
DRB1* alleles were associated with favorable prognostic signs. Apple et
al.19 hypothesized that DRB1* alleles are important in protection against cancer.
Although our study did not present significant associations between class II
alleles and risk for cancer or disease outcome, potential candidate alleles appear
to exist. We did not have tumor samples from patients for HPV DNA analysis.
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This is a limitation because disease-associated alleles may differ depending on
the presence of HPV DNA, as reported for cervical carcinomas.25
Figure 9.
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Conclusions
Results of our have led to the following conclusions:
I. High-risk HPV DNA is present in a subset of HNSCC. It exists in
episomal, integrated, and mixed forms. The viral load is significantly
higher in tonsillar specimens than in carcinomas arising from other
subsites. Coinfections of HPV-16 and other malignant (HPV-33) and
low-risk (HPV-11) types are present in HNSCC, while cutaneous types
are rare.
II. HPV DNA prevalence is low in laryngeal carcinomas. This suggests that
HPV probably does not play a major role in laryngeal carcinogenesis.
Almost all patients in our series were smokers and our study evaluated
the role of other potential prognostic factors as well. Heavy alcohol
intake predicts poor overall survival in LSCC. Heavy drinkers are also
younger at diagnosis. History of chronic laryngitis, gastro-esophageal
reflux disease, and frequent oro-genital sex contacts were uncommon in
our laryngeal carcinoma patients.
III. In vocal cord carcinomas, the lymphatic and blood vessel densities are
significantly lower than in HNSCC arising from other sites. This is in line
with the low metastasizing capacity of vocal cord carcinomas. In
addition, lymphatic and blood vessel densities correlated strongly with
each other in HNSCC. However, neither lymphatic vessel density nor
blood vessel density correlated with tumor size or had any prognostic
relevance.
IV. HLA class II alleles may have an impact on head and neck
carcinogenesis. Certain alleles are associated with good prognostic
signs. Moreover, distinct alleles may protect againts or predispose to
cancer. Larger studies are, however, required to confirm these findings.
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